DRDO licenses Mankind Pharma to manufacture anti-Covid drug 2-DG

DRDO licenses Mankind Pharma to manufacture anti-Covid drug 2-DG
New Delhi -based Mankind Pharma has received the license from the Defence Research and Development Organisation (DRDO) to manufacture and market its oral Covid-19 drug 2-deoxy-D-glucose (2-DG), the company said in a statement.
The Ministry of Defence had said in a statement last month that the drug was developed by the Defence Research and Development Establishment (DRDE), Gwalior, and clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy’s Laboratories.

A study conducted to ascertain the drug’s safety and efficacy had found that the drug accumulates in virus-infected cells, and prevents the growth of the virus, helping in faster recovery of patients hospitalised with Covid-19, and reducing their dependence on supplemental oxygen. “The anti-Covid drug from DRDO reduces the virus multiplication and alleviates cells from infection-induced cytopathic effect and cell death,” the study said.

The Drugs Controller General of India (DCGI) had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe Covid-19 infections on May 1. Government officials had also announced that the market price of 2-DG will be fixed at ₹900 per sachet, and sold by the Hyderabad-based Dr Reddy’s Laboratories. Being a generic molecule and an analogue of glucose means 2-DG can be easily manufactured and made available in large quantities. DRDO would reportedly provide the drug for free to central and state governments.